SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Objectives The use of sodium-glucose cotransporter-2 inhibitors (SGLT2-Is) has resulted in
significant benefits in patients with heart failure irrespective of left ventricular ejection fraction …

Background Cardiovascular disease (CVD) is a leading cause of death globally. Recently,
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP …

Background: Sodium-glucose cotransporter 2 inhibitors have been demonstrated to promote
reverse cardiac remodeling in people with diabetes or heart failure. Although it has been …

Sodium glucose-cotransporter 2 (SGLT2) inhibitors have been reported to reduce
cardiovascular events and heart failure in people with and without diabetes. These …

Background Sodium-glucose cotransporter 2 (SGLT2) inhibition reduces cardiovascular
events in type 2 diabetes (T2DM) and is associated with a reduction in left ventricular (LV) …

Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder associated
with various complications, including cardiovascular diseases. Sodium-glucose co …

Sodium-glucose cotransporter 2 inhibitors can improve heart failure outcomes, however, the
effects on left ventricular (LV) function remain unclear. This prospective observational study …

Sodium–glucose cotransporter 2 inhibitors (SGLT2i), or gliflozins, have recently been shown
to reduce cardiovascular death and hospitalization in patients with heart failure …

Abstract Purpose of Review The micro/macrovascular complications of diabetes cause
considerable morbidity and premature mortality. The SGLT2 inhibitors are the first diabetes …